Agile Therapeutics (NASDAQ:AGRX) Stock Rating Lowered by ValuEngine

Agile Therapeutics (NASDAQ:AGRX) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Thursday, ValuEngine reports.

Several other research analysts also recently commented on AGRX. Janney Montgomery Scott assumed coverage on Agile Therapeutics in a research note on Friday, April 12th. They issued a “buy” rating and a $4.00 target price for the company. Maxim Group set a $3.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Oppenheimer assumed coverage on Agile Therapeutics in a research note on Thursday, June 6th. They issued an “outperform” rating and a $5.00 target price for the company. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $4.00.

NASDAQ AGRX traded down $0.06 during trading hours on Thursday, hitting $1.10. The company had a trading volume of 108,543 shares, compared to its average volume of 355,556. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $1.70. The company’s 50 day moving average is $1.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.91 and a quick ratio of 8.91. The company has a market capitalization of $48.12 million, a price-to-earnings ratio of -1.90 and a beta of 0.65.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Sell-side analysts forecast that Agile Therapeutics will post -0.44 earnings per share for the current year.

In other Agile Therapeutics news, CEO Alfred Altomari purchased 20,000 shares of the stock in a transaction on Monday, June 10th. The shares were purchased at an average price of $1.27 per share, with a total value of $25,400.00. Following the acquisition, the chief executive officer now directly owns 258,568 shares in the company, valued at approximately $328,381.36. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 8.50% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 18,038 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Agile Therapeutics by 24.0% during the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 44,639 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Agile Therapeutics by 33.3% during the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock valued at $630,000 after buying an additional 104,222 shares in the last quarter. 42.38% of the stock is currently owned by institutional investors.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Featured Story: Short Selling Stocks and Day Traders

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.